UPB
Upstream Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.01
−1.15%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.73
- Revenue estimate
- $522.5K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.73
- EPS estimate
- -$0.78
- Revenue actual
- $773.0K
- Revenue estimate
- $561.4K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +4.1%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $23
- PT range
- $9.00 – $36
- Analysts
- 4
3 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026